Dr. Richard Lipton, M.D

NPI: 1982609327
Total Payments
$55,442
2024 Payments
$12,950
Companies
6
Transactions
29

Payment Breakdown by Category

Consulting$50,940 (91.9%)
Other$3,000 (5.4%)
Travel$1,007 (1.8%)
Food & Beverage$494.77 (0.9%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $50,940 15 91.9%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $3,000 1 5.4%
Travel and Lodging $1,007 3 1.8%
Food and Beverage $494.77 10 0.9%

Top Paying Companies

Company Total Records Latest Year
ABBVIE INC. $32,198 12 $0 (2024)
Allergan, Inc. $7,030 4 $0 (2020)
Acorda Therapeutics, Inc $5,622 4 $0 (2017)
Biohaven Pharmaceutical Holding Company Ltd. $4,750 2 $0 (2022)
Supernus Pharmaceuticals, Inc. $3,342 6 $0 (2017)
Biohaven Pharmaceuticals, Inc. $2,500 1 $0 (2021)

Payment History by Year

Year Amount Transactions Top Company
2024 $12,950 8 ABBVIE INC. ($12,950)
2023 $19,192 2 ABBVIE INC. ($19,192)
2022 $4,805 4 Biohaven Pharmaceutical Holding Company Ltd. ($4,750)
2021 $2,500 1 Biohaven Pharmaceuticals, Inc. ($2,500)
2020 $1,500 1 Allergan, Inc. ($1,500)
2019 $5,530 3 Allergan Inc. ($5,530)
2017 $8,964 10 Acorda Therapeutics, Inc ($5,622)

All Payment Transactions

29 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
11/25/2024 ABBVIE INC. Consulting Fee Cash or cash equivalent $3,200.00 General
11/22/2024 ABBVIE INC. QULIPTA (Drug) Consulting Fee Cash or cash equivalent $1,600.00 General
Category: NEUROSCIENCE
11/15/2024 ABBVIE INC. UBRELVY (Drug) Food and Beverage In-kind items and services $50.43 General
Category: NEUROSCIENCE
11/13/2024 ABBVIE INC. Consulting Fee Cash or cash equivalent $600.00 General
11/12/2024 ABBVIE INC. Consulting Fee Cash or cash equivalent $1,200.00 General
10/04/2024 ABBVIE INC. UBRELVY (Drug) Consulting Fee Cash or cash equivalent $1,200.00 General
Category: NEUROSCIENCE
09/26/2024 ABBVIE INC. UBRELVY (Drug) Consulting Fee Cash or cash equivalent $1,200.00 General
Category: NEUROSCIENCE
07/17/2024 ABBVIE INC. Consulting Fee Cash or cash equivalent $3,900.00 General
12/13/2023 ABBVIE INC. UBRELVY (Drug) Consulting Fee Cash or cash equivalent $18,750.00 General
Category: NEUROSCIENCE
12/13/2023 ABBVIE INC. UBRELVY (Drug) Travel and Lodging In-kind items and services $441.90 General
Category: NEUROSCIENCE
12/02/2022 ABBVIE INC. UBRELVY (Drug) Food and Beverage In-kind items and services $31.63 General
Category: NEUROSCIENCE
12/02/2022 ABBVIE INC. UBRELVY (Drug) Food and Beverage In-kind items and services $23.73 General
Category: NEUROSCIENCE
06/29/2022 Biohaven Pharmaceutical Holding Company Ltd. NURTEC ODT (Drug) Consulting Fee Cash or cash equivalent $2,750.00 General
Category: PRIMARY CARE
03/16/2022 Biohaven Pharmaceutical Holding Company Ltd. Consulting Fee Cash or cash equivalent $2,000.00 General
11/16/2021 Biohaven Pharmaceuticals, Inc. NURTEC ODT (Drug) Consulting Fee Cash or cash equivalent $2,500.00 General
Category: PRIMARY CARE
12/18/2020 Allergan, Inc. Consulting Fee Cash or cash equivalent $1,500.00 General
11/04/2019 Allergan Inc. UBRELVY (Drug) Consulting Fee Cash or cash equivalent $900.00 General
Category: NEUROSCIENCE
08/30/2019 Allergan Inc. Consulting Fee Cash or cash equivalent $4,240.00 General
08/30/2019 Allergan Inc. Travel and Lodging In-kind items and services $390.00 General
11/14/2017 Supernus Pharmaceuticals, Inc. TROKENDI XR (Drug) Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program Cash or cash equivalent $3,000.00 General
Category: AED
11/14/2017 Supernus Pharmaceuticals, Inc. TROKENDI XR (Drug) Travel and Lodging Cash or cash equivalent $175.00 General
Category: AED
11/14/2017 Supernus Pharmaceuticals, Inc. TROKENDI XR (Drug) Food and Beverage Cash or cash equivalent $60.75 General
Category: AED
11/14/2017 Supernus Pharmaceuticals, Inc. TROKENDI XR (Drug) Food and Beverage Cash or cash equivalent $59.73 General
Category: AED
11/14/2017 Supernus Pharmaceuticals, Inc. TROKENDI XR (Drug) Food and Beverage Cash or cash equivalent $40.33 General
Category: AED
11/14/2017 Supernus Pharmaceuticals, Inc. TROKENDI XR (Drug) Food and Beverage Cash or cash equivalent $6.05 General
Category: AED

About Dr. Richard Lipton, M.D

Dr. Richard Lipton, M.D is a Specialist healthcare provider based in Danbury, Connecticut. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/14/2005. The National Provider Identifier (NPI) number assigned to this provider is 1982609327.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Lipton, M.D has received a total of $55,442 in payments from pharmaceutical and medical device companies, with $12,950 received in 2024. These payments were reported across 29 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($50,940).

Practice Information

  • Specialty Specialist
  • Location Danbury, CT
  • Active Since 06/14/2005
  • Last Updated 01/29/2013
  • Taxonomy Code 174400000X
  • Entity Type Individual
  • NPI Number 1982609327

Products in Payments

  • UBRELVY (Drug) $22,598
  • NURTEC ODT (Drug) $5,250
  • TROKENDI XR (Drug) $3,342
  • QULIPTA (Drug) $1,600

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Specialist Doctors in Danbury